Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680858 | 0.82 | HRH3 (0.58) | HRH3LRRK2MAPK8MAPK10 | |
| SCHEMBL24421142 | 0.82 | HRH3 (0.58) | HRH3LRRK2MAPK8MAPK10 | |
| SCHEMBL26118389 | 0.82 | PTPN1 (0.40) | LRRK2MAPK8MAPK10 | |
| SCHEMBL23536740 | 0.81 | CHRNB2 (0.48) | NPC1RAB9AKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL25241141 | 0.79 | CHRNB2 (0.47) | NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL23960949 | 0.79 | SIRT6 (0.46) | NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL9883423 | 0.79 | OGA (0.46) | OPRK1MAPK8MAPK10NPC1RAB9A | |
| SCHEMBL7138273 | 0.78 | ALDH1A1 (0.58) | NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL30432036 | 0.77 | SMO (0.53) | HRH3KDM4E | |
| SCHEMBL24379245 | 0.77 | SMO (0.53) | HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | OPRK1 1627/4885HRH3 1904/4885LRRK2 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.